Diabetes mellitus poses a significant global health challenge, necessitating the continual search for innovative therapeutic strategies. While sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in diabetes management, their efficacy diminishes in patients with declining renal function. This study aims to evaluate the potential of phenol glucosides as inhibitors for the sodium-glucose transport protein 1 (SGLT1), a key player in glucose uptake. We identified phlorizin as a representative phenol glucoside for experimental validation. The SGLT1 protein structure (PDB ID 7wmv) was analyzed through Ramachandran plot, ERRAT score, and ProSAweb Z-score, confirming its high-quality 3D conformation. A ligand-based virtual screening approach yielded 400 compounds that matched well with our pharmacophore models, including 10 compounds from virtual libraries. Notably, two compounds stood out for their high matching scores. Molecular docking simulations revealed strong binding affinities with SGLT1, especially for the compound CHEMBL2303983 with a binding energy of -11.2 kcal/mol. ADMET analysis was conducted to evaluate the drug-likeness & safety profile of such high-affinity compounds. The compounds exhibited variable water solubility and moderate lipophilicity but were generally compliant with most drug-likeness rules. However, certain challenges such as low GI absorption and inability to cross the blood-brain barrier were identified. No PAINS or Brenk alerts were raised, suggesting a low likelihood of assay interference or toxicity. In conclusion, our in-silico approach has identified promising candidates among phenol glucosides for inhibition of SGLT1, albeit with challenges in solubility and pharmacokinetics that require further optimization. The study opens new avenues for the synthesis and experimental verification of novel SGLT1 inhibitors.